Aspira Women's Health Q2 revenue $2.4M; cuts FY cash guidance to $13-14.5M

Aspira Women's Health Inc.

2024-Q2 EPS reported -$0.67 vs consensus -$0.31 ▼ miss (-117.5%)

Q2 product revenue $2.4M vs $2.5M YoY; OvaSuite volume 6,471 units (+3%).
Gross margin 59% vs 62% YoY; operating cash used $3.7M in Q2.
Cash at June 30: $1.0M; subsequent raises of $4.0M boosted pro forma cash to $5.0M.
Full-year 2024 cash guidance lowered to $13-14.5M from $15-18M.
OvaWatch volume grew 48% YoY; John Kallassy appointed interim CFO effective Aug 15.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.